Murat Osman Arcasoy | Scholars@Duke

Murat Osman Arcasoy
Professor of Medicine

Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling

Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occuring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematology, Medicine 2016
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2012

Contact Information

Duke Box 3912, Durham, NC 27710
Hosp South Trent Drive, Box 3912 DUMC, Durham, NC 27710
arcas001@mc.duke.edu (919) 684-5350

Background
Education, Training, & Certifications
- Fellow in Medical Oncology, Medicine, Yale University 1997 - 1998
- Hematology Fellow, Medicine, Yale University 1992 - 1993
- Chief Medical Resident, Medicine, State University of New York at Brooklyn 1991 - 1992
- Medical Resident, Medicine, State University of New York at Brooklyn 1988 - 1991
- M.D., Aegean University School of Medicine (Turkey) 1987
Duke Appointment History
- Associate Professor of Medicine, Medicine, Hematology, Medicine 2009 - 2016
- Associate Professor of Medicine, Medicine, Hematology, Medicine 2005 - 2009
- Assistant Professor of Medicine, Medicine, Hematology, Medicine 1999 - 2005
Research
Selected Grants
- PU-H71 awarded by Samus Therapeutics, Inc. 2018 - 2023
- INCB 39110-209 awarded by Incyte Corporation 2018 - 2023
- PAC203 Protocol awarded by CTI Biopharma Corp. 2017 - 2022
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects awarded by Gilead Sciences, Inc. 2016 - 2021
- A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of awarded by Incyte Corporation 2017 - 2020
- Gilead GS-US-352-1214 awarded by Gilead Sciences, Inc. 2014 - 2019
- GS US 352 1154 awarded by Gilead Sciences, Inc. 2016 - 2017
- A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 awarded by Janssen Research & Development, LLC 2016 - 2017
- Erythropoietin Receptors in Breast Cancer awarded by National Institutes of Health 2004 - 2010
- Role of Erythropoietin Receptor Signaling in the Heart awarded by National Institutes of Health 2003 - 2006
- Erythropoietin Receptor Regulation of Erythorpoiesis awarded by National Institutes of Health 1998 - 2005
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Diep, RT, Corey, K, and Arcasoy, MO. "A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families." Annals of Hematology (February 12, 2019). (Letter) Full Text
  - Diep, RT, and Arcasoy, MO. "Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome." Annals of Hematology 96, no. 9 (September 2017): 1589-1590. (Letter) Full Text
  - Verstovsek, S, Mesa, RA, Gotlib, J, Gupta, V, DiPersio, JF, Catalano, JV, Deininger, MWN, Miller, CB, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, EO, Lyons, RM, Paquette, R, Raza, A, Jones, M, Kornacki, D, Sun, K, Kantarjian, H, and COMFORT-I investigators, . "Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial." Journal of Hematology & Oncology 10, no. 1 (February 22, 2017): 55-null. Full Text
  - Abril, MK, Barnett, AS, Wegermann, K, Fountain, E, Strand, A, Heyman, BM, Blough, BA, Swaminathan, AC, Sharma-Kuinkel, B, Ruffin, F, Alexander, BD, McCall, CM, Costa, SF, Arcasoy, MO, Hong, DK, Blauwkamp, TA, Kertesz, M, Fowler, VG, and Kraft, BD. "Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing." Open Forum Infectious Diseases 3, no. 3 (September 2016): ofw144-null. Full Text Open Access Copy
  - Shanavas, M, Popat, U, Michaelis, LC, Fauble, V, McLornan, D, Klisovic, R, Mascarenhas, J, Tamari, R, Arcasoy, MO, Davies, J, Gergis, U, Ukaegbu, OC, Kamble, RT, Storring, JM, Majhail, NS, Romee, R, Verstovsek, S, Pagliuca, A, Vasu, S, Ernst, B, Atenafu, EG, Hanif, A, Champlin, R, Hari, P, and Gupta, V. "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 22, no. 3 (March 2016): 432-440. Full Text
  - Lee, G, and Arcasoy, MO. "The clinical and laboratory evaluation of the patient with erythrocytosis." European journal of internal medicine 26, no. 5 (June 2015): 297-302. (Review) Full Text
  - Stein, BL, Gotlib, J, Arcasoy, M, Nguyen, MH, Shah, N, Moliterno, A, Jamieson, C, Pollyea, DA, Scott, B, Wadleigh, M, Levine, R, Komrokji, R, Klisovic, R, Gundabolu, K, Kropf, P, Wetzler, M, Oh, ST, Ribeiro, R, Paschal, R, Mohan, S, Podoltsev, N, Prchal, J, Talpaz, M, Snyder, D, Verstovsek, S, and Mesa, RA. "Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms." Journal of the National Comprehensive Cancer Network : Jnccn 13, no. 4 (April 2015): 424-434. (Review) Full Text
  - Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, Catalano, JV, Deininger, MWN, Miller, CB, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, EO, Lyons, RM, Raza, A, Vaddi, K, Sun, W, Peng, W, Sandor, V, Kantarjian, H, and COMFORT-I investigators, . "Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I." Haematologica 100, no. 4 (April 2015): 479-488. Full Text
  - Silhan, LL, Shah, PD, Chambers, DC, Snyder, LD, Riise, GC, Wagner, CL, Hellström-Lindberg, E, Orens, JB, Mewton, JF, Danoff, SK, Arcasoy, MO, and Armanios, M. "Lung transplantation in telomerase mutation carriers with pulmonary fibrosis." The European Respiratory Journal 44, no. 1 (July 2014): 178-187. Full Text
  - Mesa, RA, Kiladjian, J-J, Verstovsek, S, Al-Ali, HK, Gotlib, J, Gisslinger, H, Levy, R, Siulnik, A, Gupta, V, Khan, M, DiPersio, JF, McQuitty, M, Catalano, JV, Hunter, DS, Knoops, L, Deininger, M, Cervantes, F, Miller, C, Vannucchi, AM, Silver, RT, Barbui, T, Talpaz, M, Barosi, G, Winton, EF, Mendeson, E, Harvey, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Sun, W, Sandor, V, Kantarjian, HM, and Harrison, C. "Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies." Haematologica 99, no. 2 (February 2014): 292-298. Full Text
  - Mesa, RA, Kiladjian, J-J, Verstovsek, S, Al-Ali, HK, Gotlib, J, Gisslinger, H, Levy, R, Siulnik, A, Gupta, V, Khan, M, DiPersio, JF, McQuitty, M, Catalano, JV, Hunter, DS, Knoops, L, Deininger, M, Cervantes, F, Miller, C, Vannucchi, AM, Silver, RT, Barbui, T, Talpaz, M, Barosi, G, Winton, EF, Mendeson, E, Harvey Jr, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Sun, W, Sandor, V, Kantarjian, HM, and Harrison, C. "Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies." Haematologica 99, no. 2 (2014): 291-298.
  - Mesa, RA, Kiladjian, JJ, Verstovsek, S, Al-Ali, HK, Gotlib, J, Gisslinger, H, Levy, R, Siulnik, A, Gupta, V, Khan, M, DiPersio, JF, McQuitty, M, Catalano, JV, Hunter, DS, Knoops, L, Deininger, M, Cervantes, F, Miller, C, Vannucchi, AM, Silver, RT, Barbui, T, Talpaz, M, Barosi, G, Winton, EF, Mendeson, E, Harvey, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Sun, W, Sandor, V, Kantarjian, HM, and Harrison, C. "Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies." Haematologica 99, no. 2 (January 1, 2014): 292-298. Full Text
  - Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, Catalano, JV, Deininger, MWN, Miller, CB, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, EO, Lyons, RM, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Sun, W, Sandor, V, and Kantarjian, HM. "Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I." Haematologica 98, no. 12 (December 2013): 1865-1871. Full Text
  - Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, Catalano, JV, Deininger, M, Miller, C, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Sun, W, Sandor, V, and Kantarjian, HM. "The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis." Br J Haematol 161, no. 4 (May 2013): 508-516. Full Text Link to Item
  - Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, Dipersio, JF, Catalano, JV, Deininger, M, Miller, C, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Sun, W, Sandor, V, and Kantarjian, HM. "The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, Phase III study in patients with myelofibrosis." British Journal of Haematology 161, no. 4 (2013): 508-516. Full Text
  - Reddi, DM, Lu, CM, Fedoriw, G, Liu, Y-C, Wang, FF, Ely, S, Boswell, EL, Louissaint, A, Arcasoy, MO, Goodman, BK, and Wang, E. "Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens." American Journal of Clinical Pathology 138, no. 6 (December 2012): 855-866. Full Text
  - Kumar, SM, Zhang, G, Bastian, BC, Arcasoy, MO, Karande, P, Pushparajan, A, Acs, G, and Xu, X. "Erythropoietin receptor contributes to melanoma cell survival in vivo." Oncogene 31, no. 13 (March 2012): 1649-1660. Full Text
  - Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, Catalano, JV, Deininger, M, Miller, C, Silver, RT, Talpaz, M, Winton, EF, Harvey, JH, Arcasoy, MO, Hexner, E, Lyons, RM, Paquette, R, Raza, A, Vaddi, K, Erickson-Viitanen, S, Koumenis, IL, Sun, W, Sandor, V, and Kantarjian, HM. "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis." The New England Journal of Medicine 366, no. 9 (March 2012): 799-807. Full Text
  - Inrig, JK, Bryskin, SK, Patel, UD, Arcasoy, M, and Szczech, LA. "Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors." Bmc Nephrology 12 (December 12, 2011): 67-null. Full Text
  - McKinney, M, and Arcasoy, MO. "Erythropoietin for oncology supportive care." Experimental cell research 317, no. 9 (May 2011): 1246-1254. (Review) Full Text
  - Arcasoy, MO. "Non-erythroid effects of erythropoietin." Haematologica 95, no. 11 (November 2010): 1803-1805. Full Text
  - Rizzo, JD, Brouwers, M, Hurley, P, Seidenfeld, J, Arcasoy, MO, Spivak, JL, Bennett, CL, Bohlius, J, Evanchuk, D, Goode, MJ, Jakubowski, AA, Regan, DH, Somerfield, MR, American Society of Clinical Oncology, , and American Society of Hematology, . "American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 33 (November 2010): 4996-5010. (Review) Full Text
  - Rizzo, JD, Brouwers, M, Hurley, P, Seidenfeld, J, Arcasoy, MO, Spivak, JL, Bennett, CL, Bohlius, J, Evanchuk, D, Goode, MJ, Jakubowski, AA, Regan, DH, Somerfield, MR, and American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee, . "American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer." Blood 116, no. 20 (November 2010): 4045-4059. (Review) Full Text
  - Kransdorf, EP, and Arcasoy, MO. "Unraveling a sticky paradox." Am J Med 123, no. 5 (May 2010): 417-419. Full Text Link to Item
  - Laubach, JP, Fu, P, Jiang, X, Salter, KH, Potti, A, and Arcasoy, MO. "Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation." Exp Hematol 37, no. 12 (December 2009): 1411-1422. Full Text Link to Item
  - Fu, P, Jiang, X, and Arcasoy, MO. "Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway." Biochem Biophys Res Commun 379, no. 3 (February 13, 2009): 696-701. Full Text Link to Item
  - Pilon, AM, Arcasoy, MO, Dressman, HK, Vayda, SE, Maksimova, YD, Sangerman, JI, Gallagher, PG, and Bodine, DM. "Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2." Molecular and Cellular Biology 28, no. 24 (December 2008): 7394-7401. Full Text
  - Arcasoy, MO. "Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives." Clin Cancer Res 14, no. 15 (August 1, 2008): 4685-4690. (Review) Full Text Link to Item
  - O'Shea, SI, Arcasoy, MO, Samsa, G, Cummings, SE, Thames, EH, Surwit, RS, and Ortel, TL. "Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation." Journal of Thrombosis and Thrombolysis 26, no. 1 (August 2008): 14-21. Full Text
  - Arcasoy, MO. "Erythropoiesis-stimulating agents in cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 18 (June 2008): 3097-3098. (Letter) Full Text
  - Arcasoy, MO. "The non-haematopoietic biological effects of erythropoietin." British Journal of Haematology 141, no. 1 (April 2008): 14-31. (Review) Full Text
  - Hardee, ME, Cao, Y, Fu, P, Jiang, X, Zhao, Y, Rabbani, ZN, Vujaskovic, Z, Dewhirst, MW, and Arcasoy, MO. "Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. (Published online)" PLoS One 2, no. 6 (June 20, 2007): e549-. Full Text Link to Item
  - Arcasoy, MO, and Gockerman, JP. "Aplastic anaemia as an autoimmune complication of thymoma." Br J Haematol 137, no. 4 (May 2007): 272-. Full Text Link to Item
  - Fu, P, and Arcasoy, MO. "Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis." Biochemical and Biophysical Research Communications 354, no. 2 (March 2007): 372-378. Full Text
  - Martin, MG, and Arcasoy, MO. "Deferasirox versus deferoxamine." Blood 108, no. 2 (July 2006): 774-775. (Letter) Full Text
  - Hardee, ME, Rabbani, ZN, Arcasoy, MO, Kirkpatrick, JP, Vujaskovic, Z, Dewhirst, MW, and Blackwell, KL. "Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity." Mol Cancer Ther 5, no. 2 (February 2006): 356-361. Full Text Link to Item
  - Hardee, ME, Arcasoy, MO, Blackwell, KL, Kirkpatrick, JP, and Dewhirst, MW. "Erythropoietin biology in cancer." Clin Cancer Res 12, no. 2 (January 15, 2006): 332-339. (Review) Full Text Link to Item
  - Hanlon, PR, Fu, P, Wright, GL, Steenbergen, C, Arcasoy, MO, and Murphy, E. "Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling." Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology 19, no. 10 (August 2005): 1323-1325. Full Text
  - Arcasoy, MO, and Jiang, X. "Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor." Br J Haematol 130, no. 1 (July 2005): 121-129. Full Text Link to Item
  - Arcasoy, MO, and Karayal, AF. "Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain." Biochim Biophys Acta 1740, no. 1 (April 15, 2005): 17-28. Full Text Link to Item
  - Arcasoy, MO, Amin, K, Vollmer, RT, Jiang, X, Demark-Wahnefried, W, and Haroon, ZA. "Erythropoietin and erythropoietin receptor expression in human prostate cancer." Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc 18, no. 3 (March 2005): 421-430. Full Text
  - Wang, L, Arcasoy, MO, Watowich, SS, and Forget, BG. "Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells." Experimental Hematology 33, no. 3 (March 2005): 308-317. Full Text
  - Arcasoy, MO, and Chao, NJ. "T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil." Am J Hematol 78, no. 2 (February 2005): 161-163. (Letter) Full Text Link to Item
  - Arcasoy, MO, Amin, K, Chou, S-C, Haroon, ZA, Varia, M, and Raleigh, JA. "Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 11, no. 1 (January 2005): 20-27.
  - Arcasoy, MO, Rockey, DC, and Heneghan, MA. "Pure red cell aplasia following pegylated interferon alpha treatment." The American Journal of Medicine 117, no. 8 (October 2004): 619-620. (Letter) Full Text
  - Wright, GL, Hanlon, P, Amin, K, Steenbergen, C, Murphy, E, and Arcasoy, MO. "Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury." Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology 18, no. 9 (June 2004): 1031-1033. Full Text
  - Collins, TS, and Arcasoy, MO. "Iron overload due to X-linked sideroblastic anemia in an African American man." Am J Med 116, no. 7 (April 1, 2004): 501-502. (Letter) Full Text Link to Item
  - Haroon, ZA, Amin, K, Jiang, X, and Arcasoy, MO. "A novel role for erythropoietin during fibrin-induced wound-healing response." The American Journal of Pathology 163, no. 3 (September 2003): 993-1000. Full Text
  - Arcasoy, MO, Jiang, X, and Haroon, ZA. "Expression of erythropoietin receptor splice variants in human cancer." Biochem Biophys Res Commun 307, no. 4 (August 8, 2003): 999-1007. Link to Item
  - Arcasoy, MO, Amin, K, Karayal, AF, Chou, S-C, Raleigh, JA, Varia, MA, and Haroon, ZA. "Functional significance of erythropoietin receptor expression in breast cancer." Laboratory Investigation; a Journal of Technical Methods and Pathology 82, no. 7 (July 2002): 911-918.
  - Burns, S, Arcasoy, MO, Li, L, Kurian, E, Selander, K, Emanuel, PD, and Harris, KW. "Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis." Blood 99, no. 12 (June 15, 2002): 4400-4405. Link to Item
  - Arcasoy, MO, Karayal, AF, Segal, HM, Sinning, JG, and Forget, BG. "A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis." Blood 99, no. 8 (April 15, 2002): 3066-3069. Link to Item
  - Abdrashitova, NF, and Romanov, YA. "Functional insufficiency of the system responsible for reactive oxygen species generation by blood neutrophils." Bulletin of experimental biology and medicine 132, no. 2 (August 2001): 809-810. Full Text
  - Arcasoy, MO, Maun, NA, Perez, L, Forget, BG, and Berliner, N. "Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression." Eur J Haematol 67, no. 2 (August 2001): 77-87. Link to Item
  - "Interchangeabelity of cytokine receptor signals during terminal myeloid differentiation: erythropoietin receptor (epor) signals support granulocytic differentiation and induction of myeloid gene expression." Blood 96, no. 11 PART II (December 1, 2000).
  - Forget, BG, Degan, BA, and Arcasoy, MO. "Familial polycythemia due to truncations of the erythropoietin receptor." Trans Am Clin Climatol Assoc 111 (2000): 38-44. Link to Item
  - Arcasoy, MO, and Gallagher, PG. "Molecular diagnosis of hemoglobinopathies and other red blood cell disorders." Semin Hematol 36, no. 4 (October 1999): 328-339. (Review) Link to Item
  - Arcasoy, MO, Harris, KW, and Forget, BG. "A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation." Exp Hematol 27, no. 1 (January 1999): 63-74. Link to Item
  - Harris, KW, Hu, XJ, Schultz, S, Arcasoy, MO, Forget, BG, and Clare, N. "The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells." Blood 92, no. 4 (August 15, 1998): 1219-1224. Link to Item
  - Arcasoy, MO, Degar, BA, Harris, KW, and Forget, BG. "Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene." Blood 89, no. 12 (June 15, 1997): 4628-4635. Link to Item
  - Arcasoy, MO, Romana, M, Fabry, ME, Skarpidi, E, Nagel, RL, and Forget, BG. "High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin." Mol Cell Biol 17, no. 4 (April 1997): 2076-2089. Link to Item
  - Arcasoy, MO, and Gallagher, PG. "Hematologic disorders and nonimmune hydrops fetalis." Semin Perinatol 19, no. 6 (December 1995): 502-515. (Review) Link to Item
  - Hirshkowitz, M, Karacan, I, Howell, JW, Arcasoy, MO, and Williams, RL. "Nocturnal penile tumescence in cigarette smokers with erectile dysfunction." Urology 39, no. 2 (February 1992): 101-107. Link to Item
  - Mookerjee, B, Arcasoy, MO, and Atweh, GF. "Spontaneous delta- to beta-globin switching in K562 human leukemia cells." Blood 79, no. 3 (February 1992): 820-825.
  - Luo, XN, Arcasoy, MO, Brickner, HE, Mistry, S, Schechter, AD, and Atweh, GF. "Regulated expression of p18, a major phosphoprotein of leukemic cells." The Journal of Biological Chemistry 266, no. 31 (November 1991): 21004-21010.
  - Hirshkowitz, M, Karacan, I, Arcasoy, MO, Acik, G, Narter, EM, and Williams, RL. "Prevalence of sleep apnea in men with erectile dysfunction." Urology 36, no. 3 (September 1990): 232-234. Full Text
  - Hirshkowitz, M, Karacan, I, Arcasoy, MO, Acik, G, and Williams, RL. "The prevalence of periodic limb movements during sleep in men with erectile dysfunction." Biol Psychiatry 26, no. 5 (September 1989): 541-544. Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Academic Articles